Literature DB >> 21109067

Clinical evaluation of microbicide formulations.

Kathleen M Morrow1, Craig Hendrix.   

Abstract

The clinical evaluation of microbicide formulations presents variable and interacting challenges. Specific domains of acceptability, pharmacokinetics, and toxicity interact with each other to potentially inhibit or enhance a microbicide's efficacy. Each of these is further influenced by application and use parameters in the relative presence (or absence) of vaginal and/or seminal fluids, ultimately impacting effectiveness. Historically, acceptability of formulation and use parameters, and their concomitant behavioral influences, have been considered separately from pharmacokinetics and toxicity. While independent evaluation of these elements is necessary in some respects, we must acknowledge that this approach is not sufficient for the successful development of microbicides. Each needs to be considered in an integrated clinical evaluation strategy. This article presents the rationale for such an approach. This article forms part of a special supplement covering two presentations on clinical evaluation of microbicides from the symposium on "Recent Trends in Microbicide Formulations" held on 25 and 26 January 2010, Arlington, VA.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21109067      PMCID: PMC3053029          DOI: 10.1016/j.antiviral.2010.09.008

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  67 in total

1.  Distribution of cell-free and cell-associated HIV surrogates in the female genital tract after simulated vaginal intercourse.

Authors:  Nicolette A Louissaint; Edward J Fuchs; Rahul P Bakshi; Sridhar Nimmagadda; Yong Du; Katarzyna J Macura; Karen E King; Richard Wahl; Arthur J Goldsmith; Brian Caffo; Ying Jun Cao; Jean Anderson; Craig W Hendrix
Journal:  J Infect Dis       Date:  2012-01-25       Impact factor: 5.226

2.  The optimal analysis of MRI data to quantify the distribution of a microbicide.

Authors:  Kurt T Barnhart; E Scott Pretorius; David M Shera; Mayadah Shabbout; Alka Shaunik
Journal:  Contraception       Date:  2005-09-19       Impact factor: 3.375

3.  Assessing microbicide acceptability: a comprehensive and integrated approach.

Authors:  Kathleen M Morrow; Monica S Ruiz
Journal:  AIDS Behav       Date:  2007-06-26

4.  A model of transluminal flow of an anti-HIV microbicide vehicle: Combined elastic squeezing and gravitational sliding.

Authors:  Andrew J Szeri; Su Chan Park; Stéphane Verguet; Aaron Weiss; David F Katz
Journal:  Phys Fluids (1994)       Date:  2008-08-21       Impact factor: 3.521

5.  Women's preferences for vaginal antimicrobial contraceptives. III. Choice of a formulation, applicator, and packaging.

Authors:  E Hardy; A L Jiménez; K S de Pádua; L J Zaneveld
Journal:  Contraception       Date:  1998-10       Impact factor: 3.375

6.  A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda.

Authors:  Anatoli Kamali; Helen Byomire; Catherine Muwonge; Julie Bakobaki; Clare Rutterford; Pius Okong; Albert Profy; Romano Byaruhanga; Stella Namukwaya; Sheena McCormack; Heiner Grosskurth; Andrew J Nunn; Charles J N Lacey
Journal:  Sex Transm Infect       Date:  2010-05-05       Impact factor: 3.519

7.  Re-framing microbicide acceptability: findings from the MDP301 trial.

Authors:  Catherine M Montgomery; Mitzy Gafos; Shelley Lees; Neetha S Morar; Oliver Mweemba; Agnes Ssali; Jonathan Stadler; Robert Pool
Journal:  Cult Health Sex       Date:  2010-08

8.  Adolescents' descriptions of the physical characteristics of microbicide surrogates and experiences of use.

Authors:  E Alexandra Zubowicz; Jennifer K Oakes; Mary B Short; Michelle M Perfect; Paul S Succop; Susan L Rosenthal
Journal:  J Womens Health (Larchmt)       Date:  2006-10       Impact factor: 2.681

9.  The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial.

Authors:  Kathleen Morrow; Rochelle Rosen; Linda Richter; Anne Emans; Anna Forbes; Jennifer Day; Neetha Morar; Lisa Maslankowski; Albert T Profy; Cliff Kelly; Salim S Abdool Karim; Kenneth H Mayer
Journal:  J Womens Health (Larchmt)       Date:  2003-09       Impact factor: 2.681

10.  Acceptability of Carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South Africa.

Authors:  Gita Ramjee; Neetha S Morar; Sarah Braunstein; Barbara Friedland; Heidi Jones; Janneke van de Wijgert
Journal:  AIDS Res Ther       Date:  2007-09-27       Impact factor: 2.250

View more
  16 in total

1.  Protection of mice from a Chlamydia trachomatis vaginal infection using a Salicylidene acylhydrazide, a potential microbicide.

Authors:  Anatoly Slepenkin; Hencelyn Chu; Mikael Elofsson; Pia Keyser; Ellena M Peterson
Journal:  J Infect Dis       Date:  2011-09-20       Impact factor: 5.226

2.  Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings.

Authors:  Rochelle K Rosen; Jacob J van den Berg; Sara E Vargas; Natali Senocak; Julia G Shaw; Robert W Buckheit; Kelley Alison Smith; Kate Morrow Guthrie
Journal:  Contraception       Date:  2015-08-11       Impact factor: 3.375

3.  The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection.

Authors:  Meropi Aravantinou; Rachel Singer; Nina Derby; Giulia Calenda; Paul Mawson; Ciby J Abraham; Radhika Menon; Samantha Seidor; Daniel Goldman; Jessica Kenney; Guillermo Villegas; Agegnehu Gettie; James Blanchard; Jeffrey D Lifson; Michael Piatak; José A Fernández-Romero; Thomas M Zydowsky; Natalia Teleshova; Melissa Robbiani
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-27       Impact factor: 2.205

Review 4.  Designing and developing suppository formulations for anti-HIV drug delivery.

Authors:  Anthony S Ham; Robert W Buckheit
Journal:  Ther Deliv       Date:  2017-08

5.  Shape of vaginal suppositories affects willingness-to-try and preference.

Authors:  Bangde Li; Toral Zaveri; Gregory R Ziegler; John E Hayes
Journal:  Antiviral Res       Date:  2012-12-29       Impact factor: 5.970

6.  User input in iterative design for prevention product development: leveraging interdisciplinary methods to optimize effectiveness.

Authors:  Kate M Guthrie; Rochelle K Rosen; Sara E Vargas; Melissa Guillen; Arielle L Steger; Melissa L Getz; Kelley A Smith; Jaime J Ramirez; Erna M Kojic
Journal:  Drug Deliv Transl Res       Date:  2017-10       Impact factor: 4.617

Review 7.  The importance of the vaginal delivery route for antiretrovirals in HIV prevention.

Authors:  Lindsay M Ferguson; Lisa Cencia Rohan
Journal:  Ther Deliv       Date:  2011-12

Review 8.  Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities.

Authors:  Florian Hladik; Gustavo F Doncel
Journal:  Antiviral Res       Date:  2010-12       Impact factor: 5.970

Review 9.  Advances in HIV microbicide development.

Authors:  Joanna S Olsen; David Easterhoff; Stephen Dewhurst
Journal:  Future Med Chem       Date:  2011-12       Impact factor: 3.808

Review 10.  Designing a multipurpose technology for acceptability and adherence.

Authors:  Elizabeth E Tolley; Kathleen M Morrow; Derek H Owen
Journal:  Antiviral Res       Date:  2013-11-01       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.